The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) by Shaaltiel Yoseph since 2007.
The trader's CIK number is 1385118.
At the time of the last reporting, Shaaltiel Yoseph was the Executive VP, R&D of Protalix Biotherapeutics, Inc.. (stock ticker symbol PLX).
Also see all insider trading activities at Protalix Biotherapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2016 | PLX | 0 | $0 | 0 | $0 | 122,162 | $122 |
| 2012 | PLX | 0 | $0 | 300,000 | $2,139,000 | 0 | $0 |
| 2010 | PLX | 0 | $0 | 500,000 | $3,518,762 | 0 | $0 |
| 2009 | PLX | 0 | $0 | 238,300 | $1,571,518 | 0 | $0 |
| 2007 | PLX | 30,000 | $97,394 | 0 | $0 | 0 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2016-09-15 | PLX | Option Ex | 122,162 | .00 | 122 |
| 2012-05-02 | PLX | Sale | 300,000 | 7.13 | 2,139,000 |
| 2010-08-05 | PLX | Sale | 48,408 | 7.00 | 338,856 |
| 2010-08-06 | PLX | Sale | 4,619 | 7.00 | 32,333 |
| 2010-06-21 | PLX | Sale | 52,973 | 7.00 | 370,811 |
| 2010-04-29 | PLX | Sale | 12,691 | 7.00 | 88,837 |
| 2010-04-14 | PLX | Sale | 1,309 | 7.00 | 9,163 |
| 2010-03-23 | PLX | Sale | 127,300 | 7.02 | 893,646 |
| 2010-03-24 | PLX | Sale | 202,700 | 7.08 | 1,435,116 |
| 2010-03-25 | PLX | Sale | 50,000 | 7.00 | 350,000 |
| 2009-10-16 | PLX | Sale | 25,680 | 9.39 | 241,135 |
| 2009-10-19 | PLX | Sale | 43,120 | 9.43 | 406,621 |
| 2009-10-15 | PLX | Sale | 31,200 | 9.39 | 292,968 |
| 2009-07-06 | PLX | Sale | 100,000 | 5.04 | 504,000 |
| 2009-05-13 | PLX | Sale | 20,000 | 3.51 | 70,200 |
| 2009-05-14 | PLX | Sale | 10,000 | 3.85 | 38,500 |
| 2009-03-13 | PLX | Sale | 8,300 | 2.18 | 18,094 |
| 2007-12-17 | PLX | Buy | 5,000 | 3.35 | 16,750 |
| 2007-12-18 | PLX | Buy | 5,100 | 3.38 | 17,212 |
| 2007-12-19 | PLX | Buy | 4,800 | 3.40 | 16,320 |
| 2007-12-05 | PLX | Buy | 15,100 | 3.12 | 47,112 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Shaaltiel Yoseph (Executive VP, R&D of Protalix Biotherapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.